Skip to main content

Outcomes

Anti-inflammatory Diet Control of Rheumatoid Arthritis

Apr 09, 2021

The TOMORROW study assessed the relationship between diet and disease activity in rheumatoid arthritis (RA) patients and has shown that RA patients are more likely to have higher inflammatory diets, but that a change to an anti-inflammatory diet resulted in lower disease activity scores.

Read Article

GLP-1 Therapy in Knee Osteoarthritis

Apr 08, 2021

Knee osteoarthritis is best managed by weight loss, as the effects of most analgesic therapies have been marginal and debatable. The use of anti-diabetic glucagon-like peptide-1 therapies have demonstrated significant weight loss benefits; hence this trial evaluated the potential weight loss and

Read Article

Can Targeting RANKL in RA Heal Erosions?

MedPage Today
Apr 07, 2021

Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported.

Read Article

Implementing Smoking Cessation Programs

Apr 07, 2021

Rheumatologists are keen to the effects of smoking (increased arthritis risk, worse outcomes, blunted DMARD responses, added cardiopulmonary risks), but often do not have the resources or plan to encourage or implement smoking cessation from the rheumatology clinic. A new study details the

Read Article

Rheumatology Care Derailed by COVID-19

Apr 06, 2021

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.



Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by

Read Article

Reactogenicity Following mRNA COVID-19 Vaccines

Apr 06, 2021

JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.

Read Article

Cost Efficacy of Knee Replacement in Obese Osteoarthritis

Apr 05, 2021

Total knee replacement (TKR) in obese patients with end-stage knee osteoarthritis appears to be a beneficial and cost-effective strategy for treating. The only potential limitation is a greater risk for adverse events in those with a body mass index (BMI) of 40 kg/m2 or greater.

Read Article

Rituximab in Systemic Sclerosis?

Apr 05, 2021

No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.

Read Article

US Senate Introduces the Safe Step Act

ACR
Apr 01, 2021

The American College of Rheumatology (ACR) today commended leaders in the United States Senate for introducing the bipartisan Safe Step Act of 2021 (S. 464), new legislation that would place reasonable limits on insurer use of step therapy. This troubling practice requires patients to first

Read Article

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

Apr 01, 2021

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.



Janus kinase

Read Article

Hypertension Unaffected by Urate Lowering Therapy

Mar 30, 2021

Does uric acid contribute to the risk of hypertension (HTN)?  A recent cohort trial shows that allopurinol in young adults does not sufficiently lower blood pressure (BP).



Previous research in a small cohort of obese hypertensive kids showed that urate lowering therapy was assoaciated

Read Article

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

Mar 26, 2021

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.




  1. Analysis of CPRD registry and 15,670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY and half that

Read Article

Safety of Paternal DMARD or Biologic Use

Mar 22, 2021

A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.

Read Article

RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout

Mar 22, 2021

Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.

Read Article

Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease

Mar 19, 2021

There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.

Read Article

Are You a Super Rheum?

Mar 18, 2021

Several weeks ago, at the Rheumatology Winter Clinical Symposia, an interesting debate between Drs. Orrin Troum and Marty Bergman hashed over the concept of whether rheumatologists should sub-specialize with a practice, research or career devoted to one disease ("Super Rheum"), or be "selective

Read Article

Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures

Mar 17, 2021

JAMA Dermatology has published a Danish national cohort study showing that potent topical corticosteroid use was associated with an increased risk of osteoporosis and major osteoporotic fractures with a dose-response association for cumulative use.



Clearly systemic and inhaled

Read Article

Rheumatic Patients Are at Risk for COVID Death

MedPage Today
Mar 16, 2021

Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry

Read Article

Low Anaphylaxis Risk with COVID mRNA Vaccines

Mar 12, 2021

JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals. 



Prior studies suggested the risk of anaphylaxis to the mRNA COVID-19 vaccines may be as low as 2.5 - 11.1 cases per million doses and that such

Read Article

COVID-19-Related Deaths in Rheumatic Disease Patients

Mar 11, 2021

There is a growing body of evidence regarding COVID-19 outcomes (including death) in rheumatic disease patients; analysis of a German registry shows that poor control, rituximab, sulfasalazine and other immunosuppressives could be risk factors for COVID-related death.



The early data

Read Article

Comparison of Three Coronavirus Vaccines

Mar 10, 2021

On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available.  We've compiled a comparison table and some key information relevant to your

Read Article

Low IBD Risk with IL-17 Inhibition

Mar 08, 2021

Incident or worsening colitis is a rare complication of IL-17 inhibitor therapy; a real world study confirms very low rates of new IBD in patients starting secukinumab.



A real-world study of the secukinumab (SEC; an IL-17 inhibitor) and gastrointestinal related adverse events (GIRAE)

Read Article

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Mar 04, 2021

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article

Baricitinib Therapy in Covid-19 Pneumonia

Mar 04, 2021

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery. The key

Read Article

Weight Loss to Avert Risk of Gout

Mar 03, 2021

Analysis of the NHANES population survey data shows weight gain during adulthood increases the risk of gout and that maintaining normal weight could reduce the overall gout risk by nearly 33%.



Obesity and gout have long been linked, but the the influence of weight changes during

Read Article
×